Broxinac eye drops 0.09% 1.7ml

Broxinac eye drops - which are non-steroidal anti-inflammatory drugs, which is used in ophthalmology in the postoperative period. The drug reduces the inflammatory process and has an analgesic effect.

Bromfenac is a non-steroidal anti-inflammatory drug (NSAID), which has anti-inflammatory and analgesic action, blocks the synthesis of prostaglandins from arachidonic acid by inhibiting cyclooxygenase 1 and 2, which reduces inflammation and reduces pain.

In vivo studies have shown that prostaglandins are mediators of certain types of inflammation of the eye. In animal studies, prostaglandins contributed to the breakdown of the hemato-ophthalmic barrier, increased vascular permeability, caused vasodilation, leukocytosis, increased intraocular pressure.

Indications:

Treatment of postoperative inflammation and pain relief in patients after cataract extraction.

Contraindications:

• hypersensitivity to the components of the drug, as well as to other non-steroidal anti-inflammatory drugs;
• the use of the drug is contraindicated in patients who have attacks of bronchial asthma, hives and symptoms of acute rhinitis, are intensified when taking acetylsalicylic acid and other NSAIDs;
• age to 18 years (safety and efficacy of the drug in children have not been studied).

With caution: the sodium sulfite contained in the preparation may cause an allergic reaction, including anaphylactic shock, asthma attacks in susceptible people. Sensitivity to sulfites is increased in persons with bronchial asthma and allergic reactions in the anamnesis.

With the use of Broxinac, there is the possibility of developing cross-sensitivity to acetylsalicylic acid, derivatives of phenylacetyl acid, as well as other NSAIDs. Care must be taken when treating people who have previously been sensitive to these drugs.

NSAIDs may increase bleeding time as a result of platelet aggregation abnormalities. The use of local NSAIDs in combination with ophthalmic operations can increase the bleeding of the eye tissues (including the anterior chamber of the eye). Brosinac should be used with caution in patients who have a history of bleeding tendency, or if patients receive other medications that may increase clotting time.

The experience with the use of local NSAIDs shows that patients with complications after surgical ophthalmologic interventions, denervation of the cornea, defects in the corneal epithelium, diabetes mellitus, superficial eye diseases (eg, dry eye syndrome), rheumatoid arthritis or repeated surgical interventions for a short period time, may have an increased risk of developing side effects from the cornea.

Use in children

Contraindicated for children under 18 years.

Application in elderly patients

The regimen of the drug does not differ from that in younger patients.

Special instructions:

The use of local NSAIDs 24 hours before surgery on the eyes and within 14 days after ophthalmic surgery may increase the risk of occurrence and severity of adverse reactions from the cornea.

The use of local NSAIDs can lead to the development of keratitis. In some susceptible patients, prolonged use of local NSAIDs may cause a rupture of the epithelium, thinning of the cornea, erosion of the cornea, the formation of an ulcer on the cornea, or perforation of the cornea. These side effects can create a risk of vision loss. Patients with signs of rupture of the corneal epithelium should immediately stop using the drug and be under medical supervision until the corneal state is normalized.

The use of NSAIDs may slow the healing process, especially when combined with local corticosteroids. Patients should be warned that there may be a delay in healing during the application of NSAIDs.

When using Broxinac, patients should not use contact lenses.

Patients should be warned that they do not touch the tip of the dropper and do not touch any surface, it can lead to contamination of the contents of the bottle.

Impact on the ability to drive vehicles and manage mechanisms

The drug has little effect on the ability to drive vehicles and control mechanisms. Perhaps a brief blurred vision after the introduction of the drug, so it is recommended to wait until the full recovery of vision, before proceeding to driving vehicles and controlling mechanisms.

Suggested Use:

Installations in the conjunctival sac

One drop once a day. Treatment is started 1 day before surgery and is continued during the first 14 days of the postoperative period (including the day of the operation).

Instructions in case of missing one or more medications

In case of skipping the drug should be used as soon as possible in the dosage provided by the instruction. If the pass in the use of the drug is close to 24 hours, the drug should be applied at the next scheduled time, without doubling the dose to compensate for the missed dose.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!